Registered number: 04509293 Charity numboys: 1094231 & SC039257 The British Allergy Foundation (A company limiled by guarantee) Trustees. Teport and financlal statements For the year ended 31 Mar¢h 2023 1111 •ACIVSSTD• iY)112r2023 #109 Th• Bfltlsh Allergy Foundation IA company limited by guarantee) Contents Page Reference and admlnbtraliv• detslls ofthe Charity, Its TNstees and advlser4 Trust¢os' r•part 2-14 Ind¢pendont auditots. report on lh* fin4nci￿ statements 15-19 Consolidated statement of fil￿ncIal acdviil•s consol1da1￿ balanco she81 21 Charity balance sheet 22 Consol0dat￿ stalemenl ol cash flows 23 Nots$ to th• fin*nclal stat•ments 24-50 .The Brlllsh Allergy Foundation IA company limited by guarantsel Reference #nd administiatlvè d•taih of the Ch•rlty. its Trttste￿ and advlsws For lh• year end$d 31 Ma￿h 2023 Trnstees MS'L Prilthard, Chair Mrs A Tharani. C￿r Mr R Daby Mr R Dud*-Southem MBE Mf P Frarnpton {wnted 29 Septemb8r 2022) Or B HevAiI MT J Redding 1￿$￿Jned 24 NoveM￿r 2022) Or G st￿les Dr S Kay¢de (appointed 24 Novwnber 2022) Ms R Ok4royd {appo¢nled 23 Febwary 2023) Ms K Sykes lappointed 17 June 2023) Ms E Withers (appointed 24 November 2022) Company regi$t¢r¢d number 04509293 Charlty reglslerod numbers 1094231 aTrJ SC039257 R•gistered office London 14ouse Business Centre Thames Roal Crayford Dartlord Englar DA14SL Company sttr¢tary P Turr*ull Chlef executivo olfic•r S Miles Independent auditors Kre51on Reeves LLP ChartEYed A¢¢ounlants ststutory Audrtor 37 Sl Mar9arefs Street Canlerbury Kent CT12TU Page 1 Th¢ British Allergy Foundation IA company lim11￿ by guarantee) Trust¢•s' r•port For the year *nd•d 31 March 2023 The Trustees present Iheir annual report together wrfh the audited financial slalemenls of Ihe-charity for the 1 April 2022 10 31 March 2023. The Annul Tewrt seNes the purposes of both a Tru$lees' report and a dire¢tor$' report under company law. The Trustees confimi Ihal the Anr4Jal re￿1 and linan¢4al slaterr￿nIS of the charitable wmpany compty ￿th the eurrenl slalutory requir￿ents. the requirnnents of the charrtable company's governing document and the kXOVigOnS of the St*emenl ol Recommended Practiee ISORP) applicable lo charities preparing Iheir accounts in accordance wrfh the Fin￿￿la1 Repth'n9 Stsndard ap￿Kable ￿ the UK and Republi¢ of Irelan¢ IFRS102} leffe¢li¥• 1 January 20191. Since Ihe group and Ihe Chanty qualfy as smal under seclTh 383 of Ihe Compantes Act 20(6. Ihe Group slr81egi¢ report required of medium and companie$ under the t¢￿￿S Act 20C6 IslralegiG Report and D￿e￿Or$, Report) Regulations 2013 has been c¥nitled. The group and the Charily also trnje vThler Ihe nam Alber9y UK. ObJectlv•s and actlvS11•s . Policies Ind objectives The Chorilabb Object$ for the thariiy are: 3.1 To raise publ￿ awareness afound allergy and the causes ol anaphylaxi5. 3.2 To produce rdiable infomalion and education in the communrty for the managernenl prevenlion of all allergic reactions, indudiw anaph￿axiS. 3.3 . To Provide 5UPPOrt in the ¢(KrKnvnty to all those affecled by 8ifefgy. coverin9 all manrfeslations ol allergy lo reduce r￿k of serious allergK reactKJn (anaphylaxis). This support extends to bereaved lamlies. 3.4 To promole research into Ihe Gause and care for 811 allw9ic Condit￿nS. including 1*05e that caus anaphYIa￿s, in order lo improve health aTrJ qUal￿Y of life for people liwng with albprgy and associated diseases. 3.5 To increase the profile of and artvoca￿ for all allerg￿ ecffKlrtk)ns, induding the seri0Lt￿ss ol anaphylaxis. woviding •Jvi¢e and rep￿sentatIOn to government. industry. and otheT organisations. and being a conduit lof informalK)n and research lor a range of expert and paiient stakeholders. 3.6 To tsmpaign lor policy and legisLth've ¢haNJes to improve Ihe lives of aH people living with allergy. including Ih05e who live ￿th the risk of aDaph￿8¥1S. In s$lting Obl￿{￿eS and pkannirvj for adivitses. the Truslees have gven due consKlerntion lo general guidance published by the Charty Commis5￿ rel*ing lo publiG benefrt. indudiNJ the 9ubJance benefil.. running a charrty IP821'. Achlevements and p•rfomianc a. Maln achi•v•ments of the Charity In 2022123 we cont#)tsed lo wod( lowards ow strategic obieclives as $et oul in our Strategy for Chan9e 2020- 2025 plarts. We are ddighled lo share with you Ihe Auergy UK Impad Reporl for 2022-23 $how￿se9 the woth that we have undertaken over the last Ye￿ to ensure we conbnue to prowde support and Servi￿ lo those Iwing with allergic disease ac¥055 the UK. The report is available lo be wewed d￿lIallY on our website via the link below. with a svmmary ol key achievements mentioned hero in this rewt. hltps'.I*￿.al1elgyUk.0rglresOU1CesIa￿ergY.￿k-Impx1-repOrt-2O22-23I p￿e2 The British Alleryy Foundatlon (A Company Ilmlt4d by guafants•) Trnste•s' report (contiTrued} FOT the y•ar ended 31 March 2023 A¢hlgvwnents and p¢rtormanc• l¢ontlnu¢dl Res•arch- Llnd•rntanding Allergy Patient Charter lor Peoplo Liviftg ￿1th Alkryi¢ [￿se3$* "Allergy UK'S research 5s used lo infomi seNices we proNide. public affairs campaigns we lobby on beh811 ol the 81lergic communrty..and the $lr*e9ic approach of the Charity. Our ieal-wortd ev1(len￿ survey and focus groups in 2021 led lo a collaborat￿n tjehveen patients. careTs. ￿TricianS Alergy UK and Ihe development ol 8 Patient Charter lor People Living with Akrgic Disease. This Charter was launched al Weslminster in May 2022 with the key vision of.. A rjght to a qu81ty $18ndaTd ol care". ftyeveryone hryng *rgylhrou9h¢xrt the UK A right lo accurate information edwation." ErnFh74verment ol pat￿nts with allergi¢ condit￿n$ Its vndersland and manage Ihwr ￿￿ditIOn %wth support frcyn inforned heaihcare prolessK)nals A right to equality in sociely- Promolitin of a better awareness #nd urKletslanding of alergy so that people with allergic conditions are not discnminated against in any aspect of thwr daisy Iwes. Thg findings inforrne¢J thè devebpment ol Allergy UK'S k)ng-lerm ¢ampaign which launched in April 2022. The aim of the carnpaign is lo ￿se awareness of the ¢hallenge5 associated wrfh living wtth an alkngy, acr055 the whole spectrum ol alergic condilions. It also seeks to shilt publK perCeptR%￿ on and th& needs ol Ihose who live wilh an allergy. As a part of our campaign, ￿ a￿ ad￿caling lor prThry care lo have specralisl allergy nurses and d￿tilIanS in every Integfate¢J Care Board IICBI. IC8s are nty# resp)nsible foi commi$sionin9 allergy servÈces at a lo¢al l¥vel Iwht¢h are not spe¢iali$t sem￿) ￿K1 Akrgy UK seni CMJI a Freedom cl Information *¢qu&sl to all 42 ICB$ in March 2023. We are Ltsing the results of IhÈ ANer9y UK funded research of a nutsè-led allewy clin￿, published ￿ 2022. 10 support this campavJn,. 01 those Teferred into Ihe semce 90% of heallhcare piofessKJna15 slated that they would have referred Ihe patient into secondary care. had the clinic nol been avail*le. Incwjenlally. after being seen in the nurse led clt"ni¢. onty 5% of Ihese patients required to be refer￿ onlo to a secondary care service. The project ran belween 2017-20218nd the results were published August 2022 in Clinical and Translational Allergy." hllps'.I1onh'nelibrary.wiley.comldo￿1ulU1O.10o2l¢1E2.l218o showng improved patient pathways ond ¢osl efficienoes. Akngside this, we are rfrvhsrting Ihe evalualN of ￿lergY UK'S Dtelilian Seryice lo gather cuirenl data on Ihe impact this service has made lo famil*s who have used it. Over 1600 infants have been referred through this ser¥i¢è sin¢e its iwlion in 2015 and many have been seen lo have gone on to r￿e*ve a diagnosis ol food allergy. PreV￿￿S evalUal￿n hyhliyhled Ihe FM)silive wnpact cl this semce for famlies and support from GPS for Ihe service. Empowering- $upportMig and Infomiing Ihrough our Hèlpllne ¥nd rÈsour¢ès Our Hewline ¢onlinued to prOv￿1e essential infcimatlon and support lor the aler9￿ cornmunily Ihrougholil 2022123 wlh a 12.6% increase in calls fiom Lqst year Many cal￿r5 are an￿Ou$ about Ihw allergies. Of suspecleil allergies and Ihe Helpline has received a kjl ol calls 8bcAJl Ihe ￿￿OI1011a1 impaci of INing with this dis¢g8p. Feedba¢k Irom Ihose who use servi¢es shows us.ihey apprecote Ihe advice and care received as they ollen cannot seem lo a￿e$S other supp)rt. Allergy UK is Ihe allergy chaiity *ith in-house Clin￿ experts IN allergy. 180 calls to our Helpline required specialssl support Irom our inthou5e ￿￿rgY Nurses, wrth 48 calls r￿ded advti on eczema provided by ou Allergy Nurses. This ha5 highlight&d a need lo develop thi$ ec2ema serv¢e in 2022123 as a bespoke Se￿ICe. We wish lo thank ¢)ur Pleallh Advisory Board gnd our cb"nical Twstee5 foi Iheir expertise and conslanl support for all cal$ to our Helpline. Page 3 The Brftl$h Allergy Foundatk*n (A company limitèd by guarantee Trusl••s' r•port lcontinu￿> For the ye•r •nded 31 March 2023 Achlgv•m•nts aNI l¢ontlnu•dl Our Dietitian serv￿ has supptyted over 1600 chldren in a &￿ar wod where parents Call. often in desperat￿n. as they have been unable to have the¥ conceffls about their chihj's suspected food allergy listened lo or are unab19 to access sc4n8one wilh ihe oxpertise. 320 children ¥￿e supporteChair posrtion of Ihe European Academy of Allergy and Cknical Immunology Palient Organisation Commitlée until Otlobev 2023, after IhrÈè and a half years supporting gkjbal patient organisalions in this robe. The charity is aFso a member of Gkibal Skin, and Ihe Global Allorgy and Asthm8 Palient Plalfomi IGMPP). Al these collabwalions work to raise awareness ol the issues Ixed. seeking lo influence polKy and sthial changes lo improve equality and qualrfy ol life loi peopte livin9 wilh allergies. b. Fundralslng activities and income generation Allergy UK is registered vhth and has paid Ihe Levy required by the Fundraising Regul8tOT. The Charity is a member of the Institute ol Fundratsing and uxnplies with all required re9tslalh￿9, including ensuring. all procedures Comp￿ wilh General Data Proteclion Regulations, Ihereby protecting the data of all vtho contact the Charity. We are pleased to advise that we have nol receN*d any Compla￿1$ felatiro lo fundraising during this year. One of our key goal$ is to $lr&ngth$n our income generation capability lo $aleguaftl the long4emt future of the Charrty. Currenlty every"£1 we raise prowdes 53 pence lo deIr￿ our seryices and our objeclive is to incfeasè this contribulion. but this ss reliant on Un￿St11Cted income and grants to supporl core seryr¢es. We have four prinripal revenue streams. including i[￿)n￿ receiv￿ via Ihe charity's tradin9 subsidiary Allergy Research Limited. Communlty Fundraisln9: In 2022 we recruited a He&1 of Fundfaising and a Senior Fundraising Officer. both ol whorn have be9un lo make a real impact (x) managing and developing plans lor oiir lundraising income stream5. This has been essenlk71 lo womding support lor those lndN￿uals and compan￿5 who ale generously commilled to donating and raisin9 funds to for our chwity and for alkryic disease. Page 5 Thè Brillsh Allèrgy Foundation {A company limited by guaTante• T￿￿t*•$' r8POrt Icontlnu•d For the year wmlod 31 March 2023 A¢hl¢v•menls and p¢rlormance Icontinuedl Judith's Wish was the Christmas 2022 fvndraisiThJ ¢arryaign. The carnpaign's key obiethes were lo e￿(￿le people abovt the dangers of severe I(￿ allerg￿$. h￿h1￿jhl the need to improve the labellrrfJ of food arKI drink prp . iesources on alkng￿ disease. Corporate parfnei support has also enabled us Its launch our Youth Engagement Progr￿￿¢ in 2022. Those who supported proiects and adivilEs that look ￿ace in 2022 are also lisled in our Impact Report. and we wish io thank Abbotl, Abbw, Aj'mmune. ALK. +ecohydra. Nut{￿ba. Phzei. Poli. Robert Th￿a$. Sa￿11. Sealy. Novart15, Naroo. Endors?TheNts and Li¢ensing: Our Ifading $ubswJiary Alergy Research Limiled provide5 endorsements lor products whtch may provide supP￿t lor lh& symptoms expèri8n¢ed by peop￿ livng ￿th allergy. The company donatès all profits lo Allergy UK each year enabliny Ihe charity lo utilise these unreslricled funds lor (wèralional and olher costs. Page 6 The Briti$h Allergy Foundation {A company limlt•d by guarantee) Tw$tees' r•port (¢ontinued) For the year ended 31 Mar¢h 2023 A¢hlev¢m•nts and porformance Icontlnv•dl All donated income from the trading subsid1￿Y dKedty finances Ihe charitrfs expenditure on operational adTrvilies and slaffing resources. OperatK*nal expenolrtU￿ pro¥￿e$ a Pelpline.. Ihe funding ol a communications team lo promole awareness of allergK diseases," Ihe emF4oym¢nl of Ihree al￿rgY nurses and a dielilian to support the helpline and provide subj'ecl maitw exptrrtise on aHer9y and irnmunolcgy", a team supwting Ihe Irading aclivilies an(J inv¢fvement wrth other organisations with the s￿￿1181 fcrtus on areas of allerg￿ disease. All surpluses will be Used lo finance fulure chantable eypeDdrtUfe. either for ongoing ￿tIl￿1es. or one-off proie¢l$. The trading Subsidiary provides the Charity's prncpal fvnding source and conkn.nued lo p¢rfofm well despite the drff¢ull global economre cortditions. Both rt5 major 8¢trthlies (cperation of endorsement programmes and working with corporate partners) exceeLled expec1atio￿ for the year. Ihe budget for which had remained conservalive when considering the economic lorefasis. Our tradiro subshyiary activities are all aimed lo be of benefit towards achievbng the Charitl$ atsns to WOVKle support lor those Imng with alLergy and ra￿e awareness of allergic d15ease. Cash flow has been ck)$ety moimlored throughoul the year and all ouffiows are planned and well within the Charills le￿￿1¢¢s. H￿￿ever, in 2023124 we whl be revie4Wiry hcw much of OUT reseNes we hold in fixed lerni accounts lo ensuTe cash 11(w is not affected. The a¢tiviti¢s carned out by the Charit￿$ subsidiary, Allergy Researth Lwnrted, require higher ￿${S compared lo a charity which ortly seeks public donations. endorsement scheme independently lesls applicants. products using speaalisl laboratories al commensurate fees. Allergy Research Limited activities Inv￿ delivering pfoj$¢l$, wh￿h are $ypp(xled by sponsorship from our ¢orp(wate partners. These piojecls are aimed al increasing pubfic and heaAhcare professional knovAedge and awareness ol allergy issuès. The endorsement schemes and proje¢ls incuf ￿$1$ to enable the achievemenl of oulwnes and many of them are now delivered through digrtal solulions lor which the Charity ukn"lises third party prov*Jer5. These cosis are Govered using donated ¢onlribulKJrn5 from ¢)ur corKKJrale partngrs an(1 any surplus funds d•s￿nated lor Ihis puip05e. Tho majorily ol the Charills ￿COrne is generated. the subs•Jiary. by these two ￿eans. Financial reviow a. Golng concwn After making appropriate enquiwie5. the Tntslees have a reasonable expectation that the Charrty h8$ adeqvale resources lo continue in operational exislerKe lor the fo￿Seeab￿ fulure. For Ihis reason. they conlinue lo adopt Ihe going con¢em basis in preparing the financial Stale￿￿nts. Further details regarding the adoplion ol the going concern basis Can ￿ found in Ihe a¢countiig wlKie$. b. Reserve5 policy The Bowd of Tfuslees rev￿e￿ the reseryes polKy in accordance with thg ¢lK3ritls Strateg￿ p￿nning, operational decisions. bJd9eling and risk managwnenl pcocesses. At every Board meeting. the Truslees see the movemenl in reserves and, therefore, ale aware ol the levd of iesoNe$ held by the charity. In addition, Iho reserves position is usually f0m1al￿ rewewed {W￿e a year in February and September. Financial risk management for Ihe 9104p ind￿leS ensuring thal thwe is Suff￿lent conlingency reseive lo enable the group lo ￿Spond to an unlore5ee0 event or emergerw. The Trustees provide the CEO wrth Ihe authonty lo make financial decisions relating lo operalional need. woviding there are three lo four months conlingeney reseNes available. This is rewsiled every 6 monlhs lo ensuce good financial praclKe. 11 i8 Allergy UK'S policy Ihat any financial decision (hal woukl resull in reducin9 the conknryncy reseives lo urKler lour month5 of the charity's operational ¢o$ls woukl have lo be es¢alaled lo the Board ol Tru$lees for a d￿lSIon. Page 7 Th• British Allelgy Foundatlon (A Company limited by guarant¢#) Trn$tees' report {¢ontlnu8d) Fof the y•ar frnded 31 March 2023 The charity receives a sleady income stream from it$ twling sthTrdiary. and it Trs Mn$•Jered highly unlikely that this would ¢ease immediatety. It is assumed Ihal. foT the purpose 015etti￿ the reserves ￿¥trI, income musl be sel at a level wh￿ti is equal lo or exceeds expenw. There could. h¢￿Ver. be a sleady crf sudden redU¢th￿ in in¢ome arising from events ouiside of Allerw UK'$ conlrol and sUlf￿lent res￿e$ should Iherefore be held lo cover a stressed drop In income over a period of Six monlhs. This would 9ivg managemenl line lo lake action lo headcounU¢osts to match the kn¥er levels of inccffitr. The average mcnlhty inc(xne foi the grrAP in 2022rd3 w88 £152.070 ond 15 ￿rrenIty £130.000 (February 20231, which excludes *acy incorne. A stressed redud¥)n rate of 10% per month has been applied lo cakulating the reserve r￿uireMent. The Trustees have set a minimum reseNes requirement at Ihwg months of cuirenl average income1£390.0001 lo cover a pclential 10% slressed reduction in income over a SiX•month period. The balan￿ on ihe cc*)tingency re5er¥e al 31 Mar¢h 2023 wa$ £466.220. The ￿ting￿nCY reserye must be deposrt. a¢o)unts at a mi¥ of temi$ arml maturity date$. bul not exceeding 12 M￿lh$. to the funds lo be ￿ceSSed when required. The Trusle$s eypts¢t manapmenl lo maintain a reseNe ¢ushion * least equ￿ to the four-month minimum and musl be immedialety of any events or expendituie that mpjht Cause the reseNes lo fall below that level. The charity wdl aklays seek lo ulilise funds èbove this levd to (￿rther ils oWive$. The dwgnaled reseNes on the balance sheet ¢￿t￿l￿8 to drflerentiate free funds from those invested in fixed as$els or commiited lo ¢ther spe¢ih'¢ projects. However. des￿nated reseNes represent free reserves that have been allocated for a speafic use by Ihe Boaid and can be reallccated at thèir discretion. This difterenliales them Irom reslricle(I resew that have been r￿1ved for a $pecthc purpose and can On￿ be used lo delivef thal objeclive. c. Finan¢l•l $tatèm•nts The financial sL7lements kn Ihe yew end for 2022r23 an N￿ome of £1,524.848 and expenditure of £1.673.217. d¢¢reasiNJ ro￿1ve$ by £148.369. The chartys income was below bJd9el duè to sèvèrnl factors. Granl In¢LNY* was over £27K be¥DW budgel Individual giving nearty £7K_ 11 was initially the￿ght Ihat ts campaKJn senl (Mjt by social media would raise awareness and increase direct debts by a hwjher level. ' AddrtKJnal grant IiKome was secured. though wth Ihanks lo Garf￿d Weston. Pilkington Trust arKI Novart15. bul this was wdl below bud9et foTecasl despittr many hKJh-qualty applications lo Trusts and FoundatKJns. Recorded Gfanl funding in 2022 is higher. with some Teceipls in earty 2022 relating to projects taking place in 202213. On a ptssitive noie, ¢o$ls were well conlrcAled the year and overheads *re over £185,000 below budgel albeit this 15 mainty 5awng5 on va¢ant posts. The liading subsidkgry. AWer9y Research L¥niled {ARLI, profft 8t year eThJ was £799.908. The forecasling had been very conservative due lo the unkncmn impa¢1 ol the pandemic and giobd economy. These risks and challenges wntinuo and therefore the budgel foieca51ed for 2023124 has also ￿rned lo be GonseNative. The new credit conlrol process has alreaty shffivn good results wrth debts over 3 months old being mduced. This process conlinues and ARL Debtors had been redu￿ lojusl over £75K in earty September. d. Prlncipal rlsks and unc?rtaintie5 A slralegic risk register is maintained conlinutyjsly and feported al every charity and trading subsidiary board meetin9 and more often il needed, wlh planned mrtrg8tKm adNrties and progress on these. The impacl Irom post Covid-19 and global econ0n1￿ challenges carried forwaid into 2022123. Page 8 Th• British Allergy Foundation IA company limil¢d by guaranlee) Trustees. report Icontlnued Foi the year ended 31 Mavch 2023 E¢ohomlc ¢llmats and Cost of livlng The economic dimate and cost of11vi￿ increases we ¢ontinuin9 lo affect everyorE. inclL*Jing ¢harities. We are privileged lo have many fantast￿ SUpp￿er$ who donale and Taise lund5 for our cause. bul we have seen Some cancellalions of regular dire¢l detH"ts. 11 is vèry difficult lo ratsè funds for al￿rgY through grants Irom Tiusts and Foundations, mainly we beI￿ve becavse the impact of liwng with al￿rgY is slill not uThYerslood. In 2022rd3 we have applied for over £500k of grants bui have been unsu¢eesslul except for two Sm￿1 grants. We would like lo offer our 8ppre¢ialion lo Garf*kl west￿ and Ihe Pilkinglon Trust Founts1￿ who have both provided small grants lo our charty during this hnancial perK>d. We have also expeiienced increases in the costs of g￿d$ and services. In todals environment al charities. musl have IT systems and prograrYwrn$ io be able lo function tn Ihe modern WOrk￿aCe. corr4)ty with required legislalion and ensure the safety of data. The costs in this fiekl have been increasing considerably. Alongside Ihis. salaries have increased auoss many sectors and recnjrtmenl during 2022123 was extremely expensive and lime (￿SuM1r￿J, due lo reGruitment agency cost$ and employ8e expeclalions on salariès. BAF has aK¥ays benchmarked salaries wdl. bul a small charity lo be a>le lo fecruil experienced staff we have had lo raise salary levels. This has an onwng on finan¢e$ at a th.n￿ whon it is even rr￿e dilfi¢ult lo raise funds Ihrou9h usual lundraising and ti•Jing acliwiies. ARL ha5 seen a change in the lype of business being conlraded. is as 8 direct result of e￿nOMiC pressures faceol by companies WI￿ seek our endorsemenl seNtes. We have also found Ihal many ol our orpoiale partners. who support us Ihfough grants and sponsorship, have reduced Ihe amount of funding available. Many ol these corroanie5 have also changed their funding timeframes and in January 2023 this did raise a risk ¢)n ¢ashflow for a very $hort pericml. Our main ¢ontin9ency fund5 awe usually held in a 0￿-year fixed term account so we had funds bul could not access Ihem ￿mediatety. We review the amount held in fixed ler accounls every year and for 202W24 and Ihis cashflow query will inlom decish)n5 we make for the future year. Finance and Audll We faced a huge Challenge in 2022 as the re¢wilment of a F￿ancts Business Manager wilh Ihe Tighl skills 8nd experience lor Ihe salary we coukl offer took nearty a year. In that per￿1. we ¢Mtracted an exlemal finance agency, Oculus. who were very supportNe and prowded t￿ assucance of mainta.ning required financial management for almost len months. This was exlremety c0511y, but unavcidable. *)d meant that a lol offinance lask$ be¢8m& Ihe retr￿1 of the CEO Operalions Director. As an addilional challenge. we had planned lo ¢hanye our finan¢e syslem Irom 1￿ April 2022 and Ihe mov¢ from SAGE to XERO was inleresling. We are pleased lo advTse that 311 challenges werè ¢)veicome. bul the complexty of mtsving from one system to another c*ne at a time vthen we had appointed new auditors. Kreslon Reeves were incredibty supportive, and we would l.ke to thank our audrtOf5 for Ihetr paI￿n¢t whilst they undertook a 'deep dive. of the charity and the trading subsidiary duriNJ the audil process. The challenges outlined did dday the fi'nal audrt being signed off by Trustees and Directors. which ioc* p* In Novembei 2022 when usualty this lakes place in Seplember 2022. H(Mever. we slill submitted all required dcturr*nlation lo the Charity Commission and Companies House. and Office ol the Sccllish Charily Regulator. on time. We appointed lo the Finance Business Managef post in Novembw 2022 and ihe XERO system has been in place for a whole financial year. enabling the aud* for 202212310 rrnre smoothty. Re¢ruitment Challeng The posl-pandemic period has been a challenge as we l￿d styne kng-temi staff made deci6ion6 to felire or leave. so we had a need to recnjil staff to key posts in 2022. We were succe551ul in covering posts for ¢)ur fundraising, communications, public aNairs, helpline. project Management. youih and volunteer enga9emenl, food safely awarenes$ and finaw. Howevef. the timeframes recruitin9 some of these p05t$ were considerable. This impacted on agency costs for recruilmenl as well as contracting external consultants lo cover key roles. such as finance. 11 also meant that a bt of addilK)nal tasks fell lo thè CEO and Operalions Director lo ensuie required a¢tNit*s moved forward. We have also had a Coup￿ of these posts become vacant again and are ¢urrenlly not recruiting for these posls as we take a risk assessment 8pprtsa¢h to the conlinued uncertainly ol income during 2023124. Paje 9 The Brltlsh Allergy Foundatlon IA company limited by guarnnt••) Trustees. r•port Icontlnuedl For the year ended 31 March 2023 Albeit inilialty we had lourKI the relum lo office working and hybrKI workin9 not have too m8ny challen9es, we lound that onknafding crf new staff Into a team woJkn"n9 fomMI was GhallervJu)g post£ovid, t*there many if not 811 had worked remotety fry a bng peri(xl ol time arKI found re•connecling lo an office enwronment quite diff￿￿11. We have worked hard in 2022r23 lo support slaff embedding into Ihe charity and trading sub￿dIary. and provided staff suNeys for feedba¢k. as well as addrtional supkvl through well*éing acts'vities. W$ have inlrojuced hybrid working arrangements, whKh has created conneclNe challenges of its own lor cross-leam development and awareness of olhers, role$ responsiblrties. We held an Away Day for all slaff in July 2022, facililaled by an external coaching eyrt with the aim to bring staff tcgelher to share an understanding of each olherfs areas ofwiyk and expertise, a conneciion wilh Ihe ¢hariVs values and objectives, and for Ihe teams lo gel to kn¢y•V ea¢h olher more. In J•nu¥y 2023 w¢ he￿ on alkday act¢vity where teams shared their experiences and expertise with each other. All managers mel off-site on a second day to discuss the oulcome5 of a Belbin le￿ exercise, and lo devek*p their shared appro¥h to delweryof key obiedives for the year ahead. L•a$fr and Offic• Mov• Another unforeseen challenge has been our landknd asking us to Su￿￿￿er our lease n￿re th￿ five years early due lo their desire lo change the LK%e ol the buihjing, whi¢h Post-pandeM￿ have lots ol vacanl Off￿ space. These discussions comMer￿ed in earty 2022 and are onty just being finalised, with an offte move by the end of June 2023. There have been negolialions lo try to cover unforeseen costs but Ihere are many aspeds lo eonsider when Moving a company address and this ha$ 8dded lo other thallenges and change management for Ihe charily. We have engaged staff in all aspects oflhe move. induding a Slaff suNey lo ascertain Ihtsughis on off￿e spa¢9. 10 try lo reduce the impact major ¢hangtr can have on emp￿Ye65. We havg enSUfed Ihg ngw premises are In a locat*Jn which is easEr lo travel lo a MaJ￿lY of staff. Successlon Planning for a neY• CEO Our CEO advised the Trustees tjrectors in 2022 that lo l*alth and personal reason$, they were lookir￿ lo slep down after eight years in the role. The CEO provided an exlended notice pencAI wth a leaving dale ol 31$1 July 2023. v4hich has provhled the charity and tradsng sUbS￿lary time lo devebp a succession plan. The Trustees would like lo thank the CEO for their commilmenl lo the charity, and also thank Ihe Operalions Director, who is stepping in as interim CEO unlil a new CEO is iecrviled. Recruilmenl commenced in the lirsl quarter ol this fin8n¢ial year arKI Twstees hope to make an anrthncemenl of Ihe new incoming CEO in the near lulure.11 is a Ghallenge when any employee leaves. bul the CEO has many responsibilities lo handover bolh internally and exteinalty. It is also a change for Ihe or9anisalion to adapt to, but Trustees are ￿rtain a new CEO will be able to build upon the Chanty's successfvl a¢h*vemenls when led by Ihe ovlgoH19 CEO and ensure the ¢harily cor)linues lo provbde the best possi￿e support and seNces lor the allergic cOmw￿nrtY into Ihe future. Sustained income generation The principal financial risks laced by the Charity l* in the perf¢rri￿ of the Irading subsidiary in delivering the expected levets ol profrt as the charity remains reliant on the trading subs*Jiary donalK)n lor a maiorily of ils income lo cover ¢haritable ¢osls. Alongside the ri$ks ol r¢du¢ed donations, inabilily lo secure grant fUndl￿d 8ndltsr a redu¢lion in corporate p8rlneT trngagemenl wilh our piqeds, we also have delays to new Iraining schemes we had hope lo launch in 2022123 due to recrurtmenl chalknges The key ski115 required lo deliver this ITaining a￿ being considered and we are hopefvl that the IrainiThJ wll be launched by the end 012023124. Our 3-to-5-year f0￿Cast$ highlT9hl the need for i￿￿ased slreams to W0v￿e slabilily lor the Chauty and a551sI us in avoiding a repeal ol Ihe ne￿ lo rnaior restructure slaifing levels. Our Irading subsidiary is developing a marketing plan with ideas for income generat￿n and the charity's expenditure is being c105ely monil¢xed. Finanaal fofec3sls suggesl Ihal the Charity remains able lo fvnd op¢raling costs over the ntrxt few years. however. this remain5 an area ol coThlinuou5 challenge lor the Charity, especially rf Il w15hes lo achieve 115 fuluTe slralegi¢ objectives. The inveslmenl in diversifying Ihe Chariws income streans should reduce the polential impad of an individual slream being adversety affected but this is in a ¢limale of resource chalerKJes for many in the IhiTd seGlor, and the currenl impact and legacy of CovKI-19 means this land5rape will continue to remain demanding. Page 10 The British Alleryy Foundatlon IA c¢mpany limllad by guaranttsl Tru$tee$' r•port {continuedl For th• year end•d 31 March 2023 These financial risks a￿ mOnrt0￿ closety by the Ch*f Exe¢ulr¥e and Finance Busingss M•ager on a daity basis.'and Ihè Boartj are wovided with r8gular financi￿ updates and forecasts lo enable them lo assess the Charilvs financial Fosthon. Thi5 is a proper ￿neCtI)n of the use of desrgnaledfunds and the paymenl ol 11a￿.1rt•e5 included on the balance sheet 8131 March 2023. The cash resources have been placed on deposits ranging from instsnt access to 12- months fixed- term. in a mannef thal pro¥￿e$ for the funds lo be avaikble sh¢)ukl they be required. In Ihis way we seek lo maximise the interest earned from prudent inveslmenls while mainlaining the 8¢¢essibility of these resources. Slw¢tur•. goveman¢¢ and manag•m•nt Constllution The ¢)fganisation is 8 ¢lwitable ¢ompany f#nited by ouarantee. incorp￿ted in Augusl 2002 Iwng been first regislered as an unirscorwaied charrty in 1991. The cornpany %wa5 est*lished undgr. a Memorandum of Assoctalion which sial¢$ Ihe obiects and p￿￿er$ of the Charilab￿ company and is govemed vndei ils Articles of Assoeialion. In addilH)n lo ihe merrKlr￿dum and ArtKles ol AssotsatK•n Ihe charily also ¢)perales under the Gode of Gocd Govemance approvejj by the Nalional Cound of Volunw OTganI5al￿N￿ aThJ Charity ConNnission. b. Methods of appointh*nt or eleclion ofTwste•s A maximum of 12 Trustees can be appoin￿ there art currenlty len on the Board. as ol June 2023. The Trustees meel at least fouf tines a year at board meetings, with an Annual General MeetiThJ usually held in September. However. in 2022 the Annual General Meeling was held in November. This was b￿aUse of the final audit reports being slightly delayed. During 2022 mosl meètings were ad4led lo a hybrhl of in-pefsorb and on- line, as peimilled under Article 47 of our govern+ng document.. The Board ol TNstee$ is respon&ble lor the strategic (Jirection of the Charty and its policy. The Chief Executivè ICEOI. and appropriate members of the Execulive team, allend the Board meebngs as reqUI￿d bul have no voting righls. The diredors ol th8 company are also charty Truslees for the purposes of charily18w and setve lor 8 peri¢)d of three years but may be re-elected lor further periods ol Ihree years. w) to a 1¢>yeai p6riod. OurTruslee James Redding stepped down In September 2022 afler serving seven years on the Board. The Board woul¢J like lo say a huge thank- you lo lor his c'diary are supported by skilled ar￿ experienced team members. h. Presldent and Vlce41resSdenl Our President. Professor P. H(￿arth is.a lounder Mem1￿ of Charity. He was a Professor ofAllersy Ob)d Respirat¢)ry M￿l¢lne and Hontyary Consuhant Phys￿l3n ?￿h7n ￿ed￿lne al the University of Soulhamplon 8nd an internationally known expert who ha$ been involve(l in supporting the allergic communily throughout hL areers, inGluding Ihrough his roles a5 a prevmxjs Trustee arKS Ambassadtsr for Allergy UK. We are exlremety gratef¢Jl for his supp￿1 ovef the last lthe decades. Currenlly we have no w￿e-PresIdent. Plans for future periods During the next 12 m¢y)th5 we wll Confinue wtyking on the *"e¢tives wtlined in our ¢urrenlslralegy 2020-2025 wlh a sustained kKus on". Conlinue(I monitoring of the economic sitU8lK)n the effect this has on the Charitls income slreams and other acliwb.es Empowemienl of Ihe v￿ce ol the allergic communty through advrtacy and our'lt's lime to take allergy sefiousII carnpaign and other publ￿ reL41K￿s activities across the UK Expanding our supporter bases and ensuring we prc¥nole programmes that have a signrfKant imp8¢1 on Ihe quality ol life ol.the allergi¢ community Broadening Ihe work Ihal we we th.ng wilh UK companies. as we Continue lo diversily our kicc¥ne generation aclivilies through fundfaisng and our Irading 511b5Kliary activiliÈs Exploring new and innovatNe revenue-generaling opportunities Continue developing our volunteer and youth engagement programmes In addilKJli, we wll be welcc¥ning oui nv•V CEO and they will begÉn lo consKler the objectives for our 2025. 2030 strategy. P8ge 13 The 8ritish Allergy Foundation IA company Ilmited by guarantee) Tw$t¢es' r•port (continu￿) For tho year •nd•d 31 March 2023 Stattm•nt ol Tiust¢es' responslbllftles The Trustees {whts are also lh¢ director5 01 the Cha￿Y lor the purposes of company lawl are responsiblo for preparin9 the Trustees, report and the financial staiements in accordaft¢e wlh applicable law aTrJ Unit Kingdom Ac¢ouftting Standards IUnile¢l lfj"ngdtyn GenW￿tyAttePted A¢ccwnling Practice). c￿panY law requires the Tn￿lee$ lo prepare finarKial $talemenl$ lor each finan¢ial . Under ¢Dmpany law, Ihe Trustees musl nol approve Ihe financial statements unless they are $8tisfied that they gNe a true and fair view of Ihe $tat¢ of affairs ol the Group and the Charity and of their incoming re$ources and ap￿icatIOn of resource$. induding Iheif income and expenditUTe, for Ihal perKrfJ. In wepa¢ing those fThn¢ial slalements, Ihe Trustees are mquired to.. select svilable accouniing wlioes and then 8ppky Ihem constslwtty.. observe the Meth￿￿$ and prinoes olthe Chanties SORP IFRS 102}". make judgernenls and a¢counling estimate5 that are reasonable and P￿￿ent. state whether applic8ble UK Accountin9 Standards (FRS 102} have been fdIcv￿d. subject to any material departures disclosed and e￿￿tsned in the firw)¢ial stalem8nls' prep*e the financial stalemenis on th¢ 90in9 wKern basis unless it is inappropri*e to presume that Ihe Group will continue in busirws. The Trustees are respC￿51b1e for keeping adequate ￿ountIng reCI￿d5 thal are Su￿len1 lo show and explain the Group and the Chariil$ transactions and dixtose wrth reasonable aeeuracy al any lime the tinancial posrfion ol the Group and the Charity and enabk them lo ensure that the financial slalemenls comply with the Companies kl 20(6. They are also reswn$1b￿ lor saleguardwig Ihe assets of the Grow) and th¢ Chaiity and hence for taking reasonable steps lor the pre￿Ilon and delects.cffl olfraL¢d and olher irregularilies. DI￿10$ure of Inf¢Ymation to audito Each ofthe petsons who are Truslees at the lime when thi5 Truslees. feport is aFvoved has confirmed Ihat". $0 lar as that Trustee is aware. there is no relevant aud￿ information of whKh the charitable group'3 audit91$ ar¢ unaware, and that Trustee has taken al Ihe steps th* ought to have bw) taken as a Trustee in order lo be aware of any rdevant audit informatkin aThJ to estst4.sh that charitable grwp's auditors a￿ awa￿ of ihat. informalion. Audltovs The auditors, K￿$t()n Reeves LLP. have indKated their ¥&illingness to continye in of1￿. The designated Trustees will propose a rnotion ieapwnling Ihe ￿￿rtly$ at a meeiry ofthe Trvslee& Approved by order ol the membws of the board of Tfvslees and s￿ned on their behall by.. Ms L Prlt¢h Chair pa￿ 14 The Brlllsh Allergy Foundat5on (A company limlted by guarantee) Ind•p•ndent auditots. r•port to the Memb•Tr of Th8 British Allergy F¢)vndatloTh Oplnlon We have audrted Ihe financial sL2tenRnts of The Bnts"sh Allergy Foundattm lthè'pafenl ¢han￿le compary'l and ils subsidiaries (the 'group'i for the year ended 31 Mar¢h 2023.vkni¢h conwri5e the Consolidaled slalemenl of financial xlivilies, the Consolmdaled balance sheet, the Charity balance sheet. the Con$olidaled stalemenl of cash Ilws and the rethd r70te$. including a summary of signifKant a¢winling p(1￿leS. The Iinancial rewrting framewo￿ that has been applied in th￿r preparakn'on is apPI￿*￿e l*¥ and United lfj'ng&)m Accounling Standards. including Financ￿1 Rwting Standard 102 'The Financial Repjrting Standard applicable in the UK and Republic of Irelan￿ (United KingJNn GeneraltyAccepled Accounling Pfxttt).. In our opinion Ihe finanual slalemenls.. gwe a true and fair view of the Slate of Ihe Group's of the parent charitable companls affairs as al 31 March 2023 and of the GfOUP'S iEKoming reswrces and appI￿￿10n of resources, induding rts income and expen. The Tiustees aCknth￿e￿ge the¥ responsiblities lor compl￿"nY wth the requirements ol the Act with respect lo accounting records arKI preparat￿ of financial 51atemenls. The financial $talets￿Ats have been prepared in a¢￿[dance wth the Fffjw$ions aprArable lo ￿lIt￿$ subiecl lo the small companies regime. The financial $lalem¢nl$ were approved and ault*YF"sed for issue by Ihe Trustees and signed on theif tsehalf￿￿. Ms L Prltchard" Dale.. The noles on p&Jes 24 10 SO lo￿ part ol these fifta￿la1 slatements. Page 22 The British Allergy Foundatlon IA company limited by guarantee} Conso11dat￿ Si•iement of cash flows For tho year end•d 31 Ilarch 2023 2023 2022 Cash flows from opwating *ctlvltles Net cash (used inyprovidèd by ￿kn¥￿ie3 23 1327,0711 127,3631 Cash flows from Investlng actlvhlos Interest received Purchase of inlan9ible assets Purch8se of tangible fixed assas Purtha5e of inveslrnents Decreasellincrease) in short tem) deposit acrAJunls 5.691 15501 11,2011 2,025 (23,7591 (13.114) 141 393,098 (2,2491 Net cash provlded by Investlng actlvltles 1.691 358,246 . Change in c•$h and cash equlvaknts In the ye Cash and.cash gquivalents al Ihe be9innirrfJ of the ye 1326.380} 846.276 330,883 515,393 Cash and cash equlvalents at Ihe end ol the year 24 520,896 846,276 The noles on pages 24 to 50 form part of these fin￿Cial statements Page 23 The British Allefgy Foundatlon IA ￿MpanY Ilmited by guarantee> Notes to the flnancial statements For lh• year ended 31 March 2023 General Infomiatlon The Bvrt15h Allet9y Foundth"on is a Charitab￿ prNate ¢(wny ￿mIl￿1 by guaranieg. incorporated in En9land. Wales and S¢oUarbJ. The Iwbilty of each member in the e¥￿t of a windin9 UP bs limil•J lo £1. The registèrèd office is LorKlon Hov5e Busines$ Centre. Tharftes Ro&J. Craylord. Dartfofd. England. DA1 4SL. The principa ath.vity of the Cha1￿y KS lo increase awaieness of al￿rgY and causos of ￿aphwaX{S through seNi¢es, advo¢a¢y. ¢8rN)aigns for poliGy and kgiskili¢Jn changes. education on management and wevenlion ol allergy, supporting the allergK commLtnity. promoting research inlo causes of allergy and irnwroving quality othfe. advcKacy. *vice. supwt and information servKes. A¢countlng pollcies 2.1 Basls ol preparatlon of flnan¢lal stal•ments The financial stalwi)ents have been prepated n a¢¢ordance wilh the Charities SORP IFRS 102) - Accounting and ReportirvJ by Charities." Slalemenl ol Recommended Practice appfficable to ¢harlI￿$ preparing their axounts in ￿allce wth Ihe Financial Reporting Standard applicable in the UK and R¥puNK DI Ireland IFRS 1021 (effeetive 1 January 2019}, the Financial Repohiig Standard applieable iri the UK and Republ￿ of Irelarml {FRS 102) comp￿leS Ad 2006. The Brrtsh Alkngy Foundation rnee15 the definrfion of a publK benefit entity under FRS 102. Assels and liabilities are initialy reCC•Jni￿ at histoiical cost w tr*)saction value urAess otherwise sialed in the ielevant acC￿￿tIng policy. The Congc4Trdated statemenl of fmno81 ad*wt￿ (SOFA) and Consolidated balance sheet consolidate the financial slalements ol the Chaity * its subskliary undertaking. The results of Ihe subsidiary ale consolthted on a line by line basis. The Charity has tak•n a￿antage of the exemplion alltr*ed under 408 of the Companies Act 2rxfi and has nol presented its th ststement ol financial ac11vil￿$ vl these financial sl8temenls. Page 24 The 8ritlsh Allergy Foundation {A company Itmlt¢d by guar4n1￿) Notes to the flnanclal staloments For the year ended 31 March Z023 Accountlng pollci•s Icontlnu•d) 2.2 Income All income is re¢ognised (￿ce the Chanty has enlillemenl lo the in¢om¥. after any performance conditions ha￿ been met. rt k8 probable that the inwne v*ill be receNed and the *nounl of wKome receivable can be measured relthty. Incoming reswrces frm tharitable li&Jing actrlrties a￿ recognwl a$ folhyws.. The 50le of goojs. re¥erwJe 15 reccgnised when dM*d g¢x•J$ are sokl. The iendering of servtces- revenue i8 re(ryniseil as follcms.. Applutions for Ihe seal of approval when the appbcalion has been sNJned and the Iwm$ agreed., Renewal of Ihe seal of approval the monlh of ¢onYnencemenl ol the new period" and Services. such as training. m the the seNice$ are supplied. Vc4unlary I[￿Me is received byway of gran1$. don*ions. legacies and gifts and is included in full in the Slalew*nl of Financial Aclpirtie5 vthen r￿e1¥able. Grants. where entitthent is not conditi.onal on the delNery of a Spear￿ performan￿ by the chwty, aw ￿09Th1$ed when the ¢hanly becom￿ unconditionally enlilw lo the y[￿t. Incoming resowces fr(*m grants. *fiere ￿lated to perfrmwce and specfft deliverabks. are accounted for as Ihe charrty eams Ihe rMJhl to cons#JeialK)n by rt5 perfoThMnce. Inves1nw￿ income 15 induded when rer*ivable. Legxies are indude(I when Ihe Chènty has legal enlrfement. the amount can be measured re&abty and it is prcbable that the incoft* will be feceived. Income tax recoverable in relation to investment incOff￿ is fecoynised at the time tho investment ir¢om¢ ts r•c8ivable. 13 Exp•ndllure Resources expended are included in the Statement ol FinarK*l Aclwrties On an ￿rUal basis and have been ¢lassifRd under headings th* aygre9aie 811 ¢osts related lo the category inclusive 01 any VAT which cannot be recovered. Expendilure is recognised where the￿ is a legal or constructive d)ligalion to make paymènl to a third party. il is probable that selllemenl will be fequired and the amounl of the obligation ¢an be measured reliabty- Fundraising cosls are those incurred in seekir¥J voluntary contributions and the staging of lundraisiThJ events. Support costs Support cost$ are Ihose ¢osls inCw￿d dwectty in support of expenditure on the objects of the company. 2.4 Gov•inm•nl grants Income from governmenl granlg is included at Ihe poinl ol applicalion for the fvnds if Ihat funding is considered lo meet the criteria of rneasurabih"ly. ieliabilty ahd probatsilty. (Xherwise il is accounted Icw upon receipt Page 25 The Brllish Alleryy FoundatioTr {A ¢ompany Ilmbted by guaranle•) Nol¢$ to the flnancial stat•ments For the year ènded 31 Mar¢h 2023 Accountjng pollcigs l¢onllnu•d) 2.5 Foreign currtncies Mone18ry assets and liabilitses d￿K￿Mated in f￿agn currencie5 are translated inlo sterling at rat¢$ of exchange rulirvJ al the TepC￿￿"n9 dale. Transaclions ￿ I￿e19n currenc*s are translated into sterling at the Tale Tuh'ng on the dale d the Iransaclion. Exchange gains aNI losses are recognised in the Consc4idated stalement of financial activities. 18 Inlangible assets and amortisation Inlar#Jible assels c05ting £1.OCrtJ or mtre ao capitalssed and recc*3nised when future e¢oMmic benefits are probable and Ihe cosl or vahje of Ihe assèt can be meaSu￿d reliabty. Intangitjle a5sels we inrtia4y recc4Jnised at cost. After recognitian, under the cost model, Int￿Ible assets are me8sur•l al cost less any xcumulatsd 8m¢ylisatK)n and any ￿￿n￿lated impairment losses. Amorti$alion is provpjed on intangble assets al rates cakukled to ￿lIe off the cost of each asset on a straight-line basis over ils expected uselul lrfe. hrnorti5alion 15 promded on the bases: . Website CRM Oevewnent cosls 10 % slraight line 10 % straight line 17 Tanglbl¥ fix¢d assets and deprecialion Tangible fixed assets ¢ostirvJ or mcrfe are capilahwj and rewjnised when luture e¢onom benefrts are probable and the cost or v￿ue ollhe asset can be mea5Ufed reliabty. Tangible ffixed assets are iiNlia*y re¢c9ntsed at ¢o$t. After re¢ognilK*n. under the ¢ost model. tangible fixed assets are measured al ¢05t kess aCcumU￿1ed depreciation and any accumulated impaiimenl losses. All costs iwjrred to bring a langible fixed ass&t into its inlended workirKJ condition should be in¢1￿￿ed in the measufement of cosl. OeprecialKJn 1$ charged so as Io allocate the cost of tsngiNe fixed assets less their residual value over Ih?IK esb"rnaled useful I￿$. on a re(lucing balance basi5. Al new r￿ed assels purGhased in 2022123 and s[￿seqUent￿ are depfeciat8d on a slrawJht4ine basis. oewetyatK￿ is on the folhymng bagL8". Furniture and filtings Conyyuter & offKe equipment 25% reducing balance 25% redvcing balance 2.8 InvestmeDI$ Fixe(l asset investments are a form of financial instrumenl an¢J a￿ Init￿ty I￿09n$Sed al their transaction cosi aThY subseguentty measured at fatr value at the Balarte sheet dale, unless Ihe value eannol be measured reliabty in which case rt is measufed at cost less wnpairmenl.Jnveslmenl gains and losses, whether ￿¥ll$e￿ or uniealised. are combined and presenled as 'Gainsl{Los3es} orn inv8slments' ui Consolklaled slatem&nl ol financial a¢lNities. Investments in subskliaries are valued at C051 less prOVts¥￿ for impain)enl. Page 26 The British Allèrgy Foundatlon IA company limlt¢d by guaranle• Notes to tht finan¢lal staiements For the year ended 31 March 2023 A¢counllng polkiw l¢ontlnu•dl 19 Stocks Slo¢ks are valued at the F(x*r of ￿st and net realisable value, being the eslimaled sellin9 price less costs to Co￿vI￿te and sell. Cost is based on Ihe cost of purchase on a first in, first oul basis. Work in progres$ and finished gcK*l$ in¢We kbour and *lributable ovetheads. Al each balance SW dale. stocks a￿ assessed for impaim*nl. 11 slcd( is impaired. the carrying amount is reduced to ils selling pri¢e ￿$15 lo compkio and sell. ThB impalm￿l foss is iecognised immedtalety in profrf or loss. 2.10 Oebtors Trade and other thblots are reeognwd at the seltlement w￿unI after any Irade discount offered. Prepayments a￿ valued 8t amount prepaid net ofany trade discounts due. 2.11 C•$h at bank and In hand Cash al bank and in hand ￿ludeS cash and short4erm h￿hty liq￿d inveslm*nl$ wilh a short maturity ol Ihroe montPts or18s$ frtyn the date of a¢qUisit￿n ￿ opening of the deposrt Crf 3unilar a¢count. 2.12 L.labiliti•s and provisions Liabilities are reco3nised when Ihete is an C￿l￿10n at the Balance sheet date as a Tesull of a past event. it is probable lh* a Iransler ol econ(¥nic benerrt will be required in seltlement. orKI Ihe amount of the selllemenl Can be e51Thaled reliabty. Liabilib"es are recognised 81 the am¢)unl that the Chaiity ankn'cipaies il pay Io Sett￿ the debt or the amount il has recwved as advanced payinenl$ for the gc<•Js or $eThices rt must provKIe. ProVis￿n$ are measured at Ihe best estimate ol the amlwnts required to settle Ihe obligath￿. Where the effecl ol the l¥ne value of money is malerial, the provisKJn is based on the present value ol those amounts, discounted at the pré4ax discount rale thal reflects Ihe risks 5t)e¢ifi¢ to the lia)ilrty. The unwnding ol the dis¢rM)l 1$ recogntsed in the Consoh"dated statement ol fffiancr81 octivilies as a finance c051. . 2.13 Frnanri41 Inslrum•nts The Group onty has fnawal assets and financtal IkqbililEs of a kind thal qualfy as bas￿ financial instruments. B8si¢ finan¢k41 inslrvmènls are inilkalty recc¥Jnised al Iransaction value and subseouenlty ' measured at their Settlement value wrth Ihe exception of bank bans whith are subsequently measured al amortt5ed cost using the effeclive interest method. 2.14 Operatlng leases Rentals pwd under s)perating leases are charged to the Consol*Jaied Slat8rnenl ol Financial AclNilies on a straMJh14ine basis over the lease term. 2.15 Penslons The GTOUP operates a defined conliibulion Pens￿)n scheme the pens￿￿ charge reP￿sentS the amounts payable by the Group to the in Tespecl ol the year. Page 27 Thg Brlllsh Allergy Foundation IA company Ilmlted by guarante•l Notes to the finanelal $tat•m•nts F¢r lh• year ended 31 March 2023 Accounting poli¢i•s l¢ontinu•d) 116 Fund •¢¢ounling General fund$ are unreslrided funds vthich ￿e available IOT use at the discret￿)rt of th* Trustees in lurtherance ol the general c￿lectr￿S of the Group an<1 YthKlJ have nol been designated for other purpose$. Oesign*ed funds ccmwise unl￿triCted funds that have been sel aside by the Tru$tee$ f¢y path'cular purposes. The aim and use of each dwnaled fund Trs sel oul in the Mtes lo the financial slat¢monls. Reslricled funds are funds which are lo be used in ￿rdar￿e wth specific restr1d￿1n5 imposed by donors or wh￿h have been raised by the Group for particular purposes. The costs 01 I8ising 8nd administering such Ivnds are charged against the Specif￿ fund. The aim and use of exh Teslricled fund is set oul ii the rths t¢ the financial stslemenls. Investment in¢c*ne. gains 8nd losse$ are ollcrtaled to th¢ apprcyriate fund. Income Irom donations and legacles Unrestricted Restricted funds nd$ 2023 2023 Total lunds 2023 t1(￿atIonS Grants 36,265 36.265 122.258 122.258 36.265 122.258 158,523 . Unrestr￿ed fund$ 2022 Restricted funds 2022 Total funds 2022 tlorkali￿s Legacies Grants 34.971 16.375 11,000 34,977 16,375 25,669 14.669 62,352 14.669 77,021 P￿e 28 The British Allorgy Foundatlon {A company Ilmlted by guaranteel Notes t¢ the flnanclal stalernent$ For the year ended 31 March 2023 Income Irom Charilable *¢tiviti•s Unrèstricted fund$ 2023 Total funds 2023 Total fvnds 2022 Sale of translation cards Affiliate markeliTrJ Fee3 received 22.005 1.982 405 250 . 22.410 22,410 2,237 Income from ￿her tradlng •cti¥ities Incom• from fundrnising •v¢nts" Unrestri¢ted fund5 2023 Total funds 2023 Tol81 funds 2022 Fundr•sin9 even15 20.918 20.918 20.298 Incom• fmm trodlng sub5idlary Unr•stricted funds 2023 Total funds 2023 Total lunds 2022 Seal of approv Renewals Alleigy Friendty Produd$ Corporate partners Akrts 357.81 S 689.894 60,700 205.￿0 3.120 777 357,81S 689.894 60,700 205,000 3.120 777 479.602 642.675 81,650 355,819 3.725 5,465 AlergyAwareness Scheme 1.317.306 1,317,306 1,548,936 Page 29 The 8rftl$h Allergy Foundation IA company limited by guarantee) Note$ to the fin4n¢Sal sialem¢ffits For the year ended 31 klarch 2023 Investment Income Unrestrlcted lunds 2023 Tolal .funds 2023 Tolal funds 2022 Inl&resl received 5.891 5.691 2.043 Expendltur• on ral$lng fvnds Co$ts of raising voluniary incom• UnrestTi¢tod I￿ndS 2023 Total lunds 2023 Cire¢l costs Professional fe 2.178 2.653 2.178 2.6S3 4,831 4.831 UnreslrKled fLtnds 2022 ReslrKted funds 2022 .Tol funds 2022 recl costs Profession81 fee$ 8.845 5.425 60.319 69,164 5.425 14,270 0.319 74.569 Fundraising Ir•ding eXpe￿$￿S Unrestri¢ted Rostrlcted funds lund$ 2023 2023 Total funds 2023 Fundraising expenses 9,132 31.290 40,422 Page 30 The British Allorgy Foundat#)n IA company limlied by guarantee) Notes to the financlal $t4t?mtnts For the y¢ar enqled 31 March 2023 Exponditure on ialslng funds l¢ontlnu•d) Fundraislng trading exptrn5es Icontinuedl Unreslri¢led funds 2022 Total fund$ 2022 Fundra$in9 expenses 30.396 30,396 Expendituie on tiading $ubsidiary Unrestrlcled fund$ 2023 Total funds 2023 Total funds 2022 Cost of sales 241.719 241.719 353,332 Anatysis ol exp•ndltur• on ¢harltsble aciivities Summary by lund type Ilnfestiicted funds 2023 Total 2023 Charitable a¢lNI 1,386.245 1.386,245 Unrestl￿ted funds 2022 Restncled fvnds 2022 Total 2022 Charitable a¢tiwt 1.244.055 1.830 1,245.885 Page 31 Th¢ Brltlsh Allergy Foundatlon IA compaw limbted by guarnntee) Notsts to Ihe linan¢lal Btatenwnts For the year end•d 31 March 2023 Analysi$ ol éxpenditsre by actlvitl¢s Actlvities undertaktrn direct 2023 . Svpport costs 2023 Total lunds 2023 ChariLth actNit 1.024.622 361.623 1.388.246 A￿l￿tIeS urKlwtsken direct 2022 SupFQrt Total funds 2022 2022 Charrtable activ* 878.440 367,445 1.245.885 Axalysis ol direct costs Tolal lunds 2023 Total funds 2022 staff ¢o$ts Communications Other direct ¢￿ts 877,828 127.360 19.434 7S7.225 101,521 19.694 1.024.822 878,440 Page 32 The Brllish All•rgy Foundation IA company limfted by guarantee) Notes to the flnanclal statemenls For the year ended 31 March 2023 Anilysis of expen(liture by actlvities Icontinued) Analy$l$ ot support costs Total f￿ndS 2023 Total fvnd$ 2022 Prernises Communulions Legal & proles￿On81 General Olf￿ expenses Depfecialic F#iancial charges Goveinance costs Trustee meetings 117.758 5.292 32.889 111.753 27.450 31.$06 34.976 140.063 3,261 50,079 119.679 27.779 13.122 12.250 1212 361.623 367.445 10. Avditors. remuneration The auditors, remunerat*￿ amounts to an auditor fee of £10,350 r2022 - È8,500). and remuneratiorb in relation to the preparalK)n ol Ihe financial statements and Co￿￿"0n lax returns of £4,125 12022 £3,750). Page 33 The Brltish Allergy Foundatlon {A company limited by guarantee) Notes to the financlal statements For the y•or end￿ 31 Ma￿h 2023 11. Stsff costs Group 2023 Group 2022 Chartty 2023 Chaiily 2022 Wage¥ and salartes sock￿ secunty cosis Contribution to defined ¢ontrthition ynsion schemes 783.375 74.217 670,528 62.979 781375 74,217 670.528 62.979 20.236 23,718 20,236 23.718 877.828 757.225 877.828 757,225 Tw ex￿ratia payments were made with regards to sewement agreeme￿$ made by Ihe ¢harity {2022.. Nonel. The Ch￿lY feft il had a moral ob1w1￿ lo make these paymenls in recognilffi of th¢ indNiduals' contribution lo the charity. These ex4Jratia payinents t01al￿d £8.940. one of wh￿h was accrued al the year end wilh a bakn¢e of £3.50012022:"£Ndl. Tho average number of Pgfsons er￿ by the Chaiity d￿n9 Ihe year was as fo1ry4VS'. Group 2023 No. (*oup 2022 No. Charity 2023 No. Chafity 2022 No. He8d¢¢)uftl 23 26 23 The average heade￿nI expressed as full-lime equ[*a1￿1S was.. Group 2023 No. Group 2022 No. Chadty 2023 No. Charity 2022 No. Chairfable actiyities Generaling funds 19 12 19 12 22 19 22 19 The number of empbyees whose emp￿￿ benefrts {ex¢tsJding enwbyer pensiw wstsl exceeded £60,000 was". Group 2023 No. Group 2022 No. In the band £60,001- £70,000 In th8 band £70,001- £80.000 The key management personnel of the group comprise the Board of Trustees. Ihe Chief Executive and Operalions 01￿clor (prior year onty the Twstees and Chiel Executive). The total ernployee benefits of Ihe key managemenl personnd ol the group were £149.32812022- £84.0691. Page 34 The Brilish Allergy Foundatio IA company Ilmited by guarantee) Not•s to th• linan¢ial stalem•nts For the y¢•r ond•d 31 March 2023 12. Trust•￿. rnmun•ratlon and •xp8nsos Durirfj the year, no TrU￿ee$ recefftd any remuneratw or other beneffts {2022 - £NIL}. Duriro the year. ended 31 March 2023. expenses lotsling £2,823 wete reirtiursed or" paKI dir8cUy lo 5 Trustee$12022- 2 Trustees received a total cl £1.1781. These related to lrnvel and hotel costs lo altend Board meetings. 13. Intangible assets Group CRM Development Costs Website Total Co$1 At 1 April 2022 Additions 107.102 550 150.562 257.664 $50 Disposals 132.7211 15,9181 138,6391 At 31 March 2023 74.931 144,644 219,$75 Amortisatlon At 1 April 2022 Charge for the year 64,173 5,983 62.974 15.056 127.147 21.039 Al 31 March 2023 51310 75.844 127,054 Net book valu At 31 Mar¢h 2023 23.721 68.800 92,521 At 31 March 2022 42.929 87.588 130,517 Page 35 The 8rltlsh Allergy Foundatlon IA company limited by guarantee) Nolas to the fmanclal statefflenls For the year end￿ 31 March 2023 13. Int•ngibl• as$•ts l¢onlinu¢d) Ch*ity CRM D•v•lopm•nt Costs Websbte Total Cosl At 1 ApiA 2022 Addrtion$ Disp¥)sals 102,546 150.$62 253,108 sso (34.0831 128.1651 KIS,9181 144,644 Al 31 March 2023 74.931 219,57S Amortlsatlon At 1 Apfil 2022 Charge lor the year 61.908 S.$6S 62,974 15.056 124,882 20.621 At 31 March 2023 Sl,210 75.844 127,054 Nel book ¥•lue At 31 March 2023 23,721 68,800 92,521 At 31 March 2022 40,638 87.588 128,226 Page 36 The Britl$h Alltrgy Foundation IA company limlted by guarantee> Notes to the flnanclal statements For tho year end￿ 31 Ma￿h 2023 . 14. Tangibl* fixed assots Group Comput¢r & ofllco equipm•nt Fumlturè & fittin9$ Total Cost or valuatlon Al 1 April 2022 Addrtions Disposals 61.911 86.777 1.201 (34,4071 148,688 1,201 {81,8631 147,456) At 31 March 2023 14A55 53.571 68.026 Depmclatlon Al 1 April 2022 Chaige lor the year On disposals 48.992 3.160 {45.318) 72.265 3.829 132.129) 121.257 6.989 {77,4471 Al 31 March 2023 6.834 43,965 50.799 Nel book valu• Al 31 March 2023 7.621 9.606 17,227 At 31 March 20Y2 12.919 14.512 27,431 Page 37 Th¢ Brltlsh Allergy Foundatlon IA company lin*ted by guarantee) Note$ to th• finan¢lal ststThnts For tho year ended 31 Ma￿h 2023 14. Tangible fixed assets Icontinuedl Ch•rity Computor & office equipmgnl Furnlture & fft¢ings Total Cost or ¥aluatlon At 1 April 2022 Addrtions 'sposals 61,911 71,720 1,201 122,0131 133,631 1.201 169.469) 147.4561 At 31 March 2023 14.465 65,363 Depreciation At 1 April 2022 Charge for the year On disposals 48,992 3.160 145.318) 57,920 1,670 (20.098 106.912 6.830 165.4181 At 31 March 2023 6￿34 41,492 48.326 N•t book value Al 31 March 2023 7.621 9,416 17.037 Al 31 March 2022 12,919 13,800 26.719 Page 38 The 8rblish Allergy Foundatlon IA company Ilmited by guar4ntsg1 Notes to the Ilnan¢lal statement5 Foy the y•ar ended 31 March 2023 IS. Flx8d ¥￿t Investments Inveslments In subsldlary. panles . Group Cost or v*lyatl¢)n At l April 2022 14 At 31 March 2023 14 Inv￿lm8nts subsidiary ¢ompanies Char5ty Cost or valuation At 1 April 2022 16 At 31 March 2023 16 Page 39 The Brit15h Allergy Foundatlon IA company limited ty guoiantet) Notès to the flnan¢lal stat•m•nty For the year ended 31 March 2023 15. r￿fjd asset Investments (¢ontlnued) Prin¢lpal $ubsldlarles The foll¢Ning were subSTdiwy L￿dertaking9 of the Charity. N8mes Company Reglst¢red office or Class of Holding In¢luded Sn numb•i prlncipal place of buslness shares Con￿li￿all0n Allergy Researth Ltd 03550847 Plwmell House Lefa . . ord￿ary 1CQ% Yes Business Park. Edgiryton Way. Sidcup. Kent. DA14 5BH 06302734 Planwell House Lefa Business Park. Edgington Way. Sid¢up. KenL DA14 SBH C6300759 Pknwdl Hovse Lela Business Park. Edgin9tTr) Way. Sidcup. Kent. DA14 5BH Allergy England Ltd lo￿￿1> 08494679 Plan*￿1 House Lets . Business Pth. EiJgi￿tOn Way. Sfvjcup. Kenl. t)A14 5BH AleTgyScotland Lld SC447980 272 Bath Slreel Glasgcrtv. Ordinary 100% No IDtsmanti G2 4JR Allèrgy Evrope Ltd (Domiantl ￿95950 Planwdl House Lefa Business Park. Edgirig10rt Way. Si(kup. Kent. DA14 5BH Alergy N¢rthem Ir¥laThd Ltd N1679729 $8, Anlrim Enterprise (Dormanll Agenw. Unit 19 Greystone Road, Anlrim. ￿ftty Antrim, Northem I[eL￿d. BT41 1JZ Allergy Wales Ltd {Dormantl 1345W6 Internaknona House, 10 Churchill Way. Carthff. Unrted Kingdom, CF10 2HE Alergy UK Ltd {Dormanl) OrdNwry I￿)% No Allergy Awa￿ Scheme Ltd (Dormanll Ordinary 100% No Ordinary 100% No Ordinary 100% No Oidinary 100% No Ordinary lo￿ No The financial results of Ihe subsKliar*s for Ihe year were.. N•mes Income Ex￿ndit￿r0 N¢t assets Aller9y Research Lld Allergy UK Lld IOJ Tf8nsfers inlout Balance al 31 March 2022 Balance at As rtstsled As reslaled l Aw'l 2021 Ine4•nE Expenditure Unrestrlcted fund* DesTrgnat•d funds Awareness Caffwtgn ReseNe Resource BuildirvJ ReseNe IT Reserve {44.880) 5,120 100.291 10,000 42.562 26,720 466,220 75,0(Kl 100.291 10.OtKJ 50.OCKJ 21.747 466,220 75.000 Fundraising Reserve Fix¢d Asset Fund Conlin9¢ncy Fund Projed Delivery Restrr¥e Public Allairs Canpaign Reserye (T.438) (8,142) 13.115 (33.605} (6.638) so.o {409) 16,395 14,795 Media ReseNe 21.1￿¥ 650 794.448 650 {11Y).7011 62,7C6 757,103 As restated Balance al Transfers 31 March inloul 2022 Balance at As restated As ￿stated - 1 2021 Incon* Expenditu G¢neral funds General Free Reserve Al￿rgY Rese¥r¢h Lthiiled 267.818 21.181 1.635.216 (1.S41.352) 139,356> 322.326 21,181 288,999 1.635.216 11.541.352) {39.3561 343,507 Total Unreslricted funds 1.083.447 1.635.866 (1.642,0531 23.350 1.100,610 Page 45 The British Allergy Foundalion IA ¢ompany limited by guarant¢t) Notes to the finan¢lal statements For th• y•ar ended 31 March 2023 stst¢m•nt of funds {¢ontinu•d) As cesLited Tran$fers ithut Balance al 31 March 2022 Bafanc* al As reslaled As restated 1 hpn'l 2021 Income Expendituie Re51rktsd funds HCP Scolland Trainw)g Fund Digttal Media Over The Wall- Camp in I Cloud Research Piojed )varti$ Global Skin 6CO 25.OCA) 11801 (1.6501 420 123.350> 1,719 . 58.6LKI (1,7191 {58.6001 13.261 13.261 1.408 85.919 14.669 162.1491 123,350) 15,089 Total of funds 1.169.3e6 1.650.$35 11.704.202) 1,115,699 Th• HCP Ih•alth care prof•s$lonal) S¢olland Training Fund is to en** Ilw Ch￿lY lo encourage training in aller9y. by making grants lo committed HCPS lo meet a percenla9e of their Iraining cosls, at a t¥ne when the Heatth Service has reduced th￿.1 funding in thts area. Novartis pfowded funding lo create t%KJ webinars developed for healthcare professional$, particularfy in primary care, to raise •¥areness of CSU as a disease ntst related lo ¥llefgy. wth authoritalive guid8n¢e on management. including onward referra. Also to create an infographic to help present an understandable oveNew of Ihe twtmenl and man•aemenl ol CSU. A leaflet lo inloim palients ol management and care palhways lo new targeled Ireatments. Offering helplul informal•)n lor paI￿nIS lo support their engagèment wih tha'r GP. Global Skln made a gianl for the review ¢f Albrgy UK'S ¢urrent eczèma resources on Allergy UK'S website and update where needed. A pc*Jcasl on lTrJing with eczema vthh a larget database. along ￿￿th a funds lor a Facebook add for Worfd Eczema Day. Sanofl Youth is in reLab'on io Dew10￿t olywlh En9agemonl wsth AIW. Nutricia is a Sponsorshp to devebp and delNer educational acliwlies that are benefKial to the alkn9iC cLwnmunity. ASmmunt aims to lase awareness with healtFKare profe55K)nals ol the vnpaci of fotyj ¥lkgry and Iho emerging pathways to prevent and mar￿e this condition. Garfleld Weston is lo help fund the operathjn of the Allergy helpline. Pfizer fund is for W￿lL￿1r￿j a l>ooklet.on skin to skn"n. knfiel on Atpoic Èczema a ￿al￿t on Eczma blood moniloring. Page 46 The British Allergy Foundatl¢)n IA company Ilmll•d by guaranlee) Notes to th• financlal statements For the year ended 31 March 2023 21. Sumrnary ol fonds Summary of fund$ • current year Balan¢• at 31 March 2023 Balanco at 1 April 2022 Trnnsf¢rs inlout Income Expèndlturo Designaled funds General lunds Restr￿led.{￿ndS 757.103 1248.1431 343.607 1.402.S90 (1.393.T84) 16m9 122.258 131.2901 12,8531 2.853 506,107 3SS,166 106,067 1.116.699 1,524.848 11,673.2171 967.330 Summary ol lunds. prior year As r&$tated Translers i￿o￿t Balance al 31 March 2022 Bkn al A$ r$staled As r¢slated 1 April 2021 Income Eyndrtur• Oesignaled funds Genw81 funds Reslricled fvrtds 794.448 288.999 85.919 650 1100,701) 1,635,216 {1,541.352) 14,669 162,149> 62,7C6 139,356) 123,3501 757.103 343.507 15.089 1.169.366 1.650.S35 (1.704.202} 1.115,699 Page47 The 8rltl$h Allergy Foundatlo IA Company IlmSled by guarantee) Notes lo the financial statements For the y*ar end•d 31 Mar¢h 2023 21 Anatysls of net assets belwoen funds Analysls of ngt assets b•twwn fvnds- curront year Unw¢stri¢led R•stri¢tod fund$ funds 2023 2023 Total lund$ 2023 Tangibk fixed assets Intsngibb fLxed assets Fixed asset inveslments Current 0$5els Credit￿5 due within one ye 17,227 92.521 14 1,172,*9 (421,4581 17.227 92.521 14 106,057 1.279,026 (421,4581 Total 861.273 106.057 967,330 Analysis of net assets between fund$- prlor y•ar Unreslricted funds 2022 ResliKled funds 2022 Total funds 2022 T8ngibk fixed assets IntsngiblÈ fixed assets Fixed asset investments Current assets Credrtor5 due within year 27.431 130.517 14 27.431 130.S17 14 1,695.291 1737.554) 1.680,202 1737,554} 15,089 Total 1,100.610 15,089 1.115,699 Pffje 48 The Brltish Allergy Foundat5on IA Company Ilmlted by guarantee) Not•s to the financial $talen￿nts For the year ènded 31 Mar¢h 2023 R¢¢onclliallon of n•1 movement In funits to net Cash Ilow from owratln9 a¢tfvllles Group 2023 Gioup 2022 Nel expenditure fcK the year {as per StaleThnt of Financol Actr￿8$) {148.3691 153.667) AdAustments tor: Depre¢iation ¢harges Amortisatson Charges Inleresl re¢eived Profil on di¥)osal of inlang Piofil on disposal of fixed asset$ Increase in stocks Decreasel(Increasel in debtors {DeC￿a$ey1ncrea5e in creditors 8.379 20,093 12,02S) 21,039 {5,691) 17.507 4.416 12rxi) 93,334 1316.0961 1161) 1130.3641 130.382 Net cash used in operathw a¢ll¥itles 1327.071) 127.3631 Aftalysls ol cash and cash equivalents Group 2023 Grtsup 2022 Cash in hand 520.896 846,276 26. Analysis of changes In n•t d•bt At 1 Aprll 2022 Ca$h Ilows At31 Maf¢h 2023 Cash al b8nk and in halrd Liquid in¥estmenls 846,276 (325,3801 2.249 520,896 462,249 1.306.276 1323,1311 983.145 P￿e 49 Th• British Allergy Foundation IA ¢ompany limit•d by guarante•l. N¢t•$ lo th• linanclal statsm•nts For th¢ yèar •nded 31 M•r¢h 2023 26. P•n$lon commitinents ' The Gro￿ cyerales a defined c￿￿"bUt10n pensNJn schm for its emF4)yees. Th&. pension cost charge for the period represents conlrt)vlKJns paydble by the Charty to the scheme arml amounled lo £20.236 12022 - £23.7181. Al Iho balance sheel dal# £N￿ was rewnised as a 1k1￿.1itY owed lo the scheme12022 - £Nill. Opeiatlng leas• commllments At 31 March 2023 the Group and the Chairty had corrmltrn￿S lo make luture rninimum b8a5e payments under non